{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-002826","form_type":"8-K","ticker":"REGN","cik":"0000872589","company_name":"REGENERON PHARMACEUTICALS, INC.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.565213+00:00","generated_at":"2026-05-28T04:16:32.485328+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Regeneron reports 2024 prelim EYLEA sales $6B; Libtayo >$1B; Dupixent >1M patients; pipeline updates","bullets":["EYLEA HD and EYLEA aggregate U.S. net sales $6B for 2024 (+1% YoY); Q4 combined $1.5B (EYLEA HD $305M).","Libtayo exceeded $1B in 2024 annual net sales; Phase 3 adjuvant CSCC shows 68% risk reduction vs placebo.","New Truveta collaboration to sequence up to 10M additional individuals; RGC has sequenced ~3M people.","Preliminary Q4 2024 IPR&D charge ~$14M pre-tax, expected to impact GAAP and non-GAAP EPS by ~$0.11.","Dupixent now used by over 1M patients globally; linvoseltamab BLA resubmitted with launch anticipated mid-2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-002826","json":"https://secwatch.observer/filing/0001104659-25-002826.json","markdown":"https://secwatch.observer/filing/0001104659-25-002826.md","text":"https://secwatch.observer/filing/0001104659-25-002826.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/0001104659-25-002826-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T04:16:32.485328+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}